Cambridge Cognition Share Discussion Threads

[40 fathoms] 07/7/2023 02:00

FDA Grants Traditional Approval for LEQEMBI for the Treatment of Alzheimer’s Disease !!!

The label approved is just about as broad as could have been hoped for, this is excellent news for Cambridge Cognition. The starting gun for the AD therapeutic gold rush has just been fired and we are one of only a handful of stores in town selling picks and shovels.

[40 fathoms] 23/6/2023 12:35

A decent dive in to what Cambridge Cognition does.

[40 fathoms] 13/6/2023 07:53

"Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce it has won a £2 million contract for a pivotal cancer therapy trial. The Company will provide its proprietary cognitive assessments (CANTAB®) as an exploratory endpoint with revenue from the contract expected to be recognised over the next five years."

Excellent, another chunky contract and all the better for being in an non CNS trial as a safety endpoint.

[40 fathoms] 09/6/2023 07:39

@WTT as you say sloppy indeed. I have already submitted my vote against the disapplication of pre-empmtion rights resolution.

[w t tutte] 09/6/2023 07:27

Today's RNS is a bit embarrassing.

How is it possible that this was not picked up ? The AGM Notice would have (maybe should have is a better phrase) been reviewed, at a minimum by the Board, the Nomad and the Company Secretary.

For context, as it is not explained in the RNS, the disapplication of pre-emption rights resolution was voted down at last years AGM, by a significant margin. However, in the recent AGM notice, it was stated that this resolution had in fact been passed and that voting in favour of the resolution at the forthcoming AGM would be a continuation of an existing authority. This is very sloppy indeed.

I am not keen on being diluted here, so again, this year, I will be voting against this resolution.

[40 fathoms] 07/6/2023 15:50

I doubt it is intentional but as you say it does not encourage direct attendance, it is about time that all companies conducted virtual AGMs. I would make this a listing requirement.

[cerrito] 06/6/2023 08:04

I see the AGM is at the not very welcoming hour of 10am especially as it will be a trek for many people. I interpret that as saying do not come, although I guess the Chair would say the Capital Markets day, which I assume will be recorded, will be more important.

[earwacks] 31/5/2023 07:51

That would explain announcement of their ‘Capital Events day’ on June 14th. Definitely slipped off the radar a bit when they actually appear to be doing quite well. Good sign being too busy though. Some companies seem to spend all their time trying to flirt with the markets.

[40 fathoms] 31/5/2023 03:30

In the last few weeks there seems to have been a bit of a corporate branding refresh, much better in my view, the old corporate branding was looking very dated.

[w t tutte] 07/5/2023 14:20

We finally have confirmation that CANTAB (Cambridge Cognition's Cognitive tests) is being used in the INTUITION Study. This by far the largest study of this kind ever undertaken, it is a huge 25,000 person study sponsored jointly by Apple and Biogen. This is a ground breaking study and the early results included in the academic paper seem to indicate that their tests that are are carried out on IPHONEs and Apple Watches produce results that are comparable to traditional pencil and paper tests. The key conclusion is

" Reliability findings were comparable to those reported in the literature for supervised cognitive assessments. These initial results suggest remote and unsupervised cognitive testing is plausible and sufficiently reliable and can be self-administered in ecologically valid real-world settings."

This is huge, firstly the potential link with Apple but secondly the validation that CANTABs short, self administered tests ( take about 8 to 10 mins, can be taken at home on your own device and repeated often) are comparable to supervised cognitive assessments (typically take 45 to 60 mins, need to be supervised by a neuropsychologist at US$ 800 per hour, taken at a testing centre using pencil and paper.)

[earwacks] 04/5/2023 14:50

Thanks for posting that 40f. All sounds very encouraging. Seems like yet another numpty fund manager has been selling up. Very low volumes all round at the moment unsurprisingly.

[40 fathoms] 04/5/2023 09:14

Directors talk post results interview

[40 fathoms] 03/5/2023 13:59

A paraphrased summary of the Dowgate note from this mornings analysts call.

- Lots of interest in the sector
-Pharma needs rigorous evidence that CNS drugs are effective. CamCog provides that evidence.
-Now only CNS company that can end to end solution for patient facing facing stages of complex CNS clinical trials
- Positioned for accelerated and sustained growth and profits
- Establishing Partnerships (?)
- Synergies from recent acquisitions, will be profitable in 2024
- Now bidding for much larger contracts
- Now bidding for contracts could not have accessed last year (given expanded offering)
- Great opportunities in Pipeline
- Any further M&A will be focused on opportunities with profits
- Working on several major deals, not clear when will be signed
- A couple are multiple millions of dollars
- Will see a higher percentage of Phase III trials
- R&D and admin cost will start to fall as a % of revenue
- Winterlight has been exploring generative AI for sometime, the scale and frequency of data CAMCOG collects makes huge and unique datasets which is very appealing to the sector. Still at very early stage. Particularly for multimodal data sets.

[earwacks] 03/5/2023 11:41

Confirming the January update ahead of expectations and 25 percent growth when the shares went up to 1.28 and now down to 94p clever market.

[40 fathoms] 03/5/2023 07:40

Before today broker numbers had a loss of less than 1 million for 2023, cash is 8.3 million, one would think they have both belt and braces in this regard. They did include this in the RNS

"Cambridge Cognition ended 2022 with sufficient cash to acquire Winterlight and fund expected growth through to profitability. "


I think a few large contracts and the RNS suggests there maybe a few waiting in the wings and the share price will respond according.

[cerrito] 03/5/2023 07:31

Yes good stuff here and am happy with my holding though as I have enough for me do not see myself adding or selling in the immediate future following recent sub 100p purchases.
I would have preferred a Going Concern Statement and my assumption is that no equity raise needed.
I did note this which may dampen any share price increase this year

Quote
While low double digit revenue growth is expected in 2023, the positive impact of acquisitions and continued investment in product development is expected to see a decrease in cash balances and operating losses for the year. With this investment and the associated increase in scale, we anticipate a return to profitability in the second half of 2024 and growth in profitability thereafter.
Unquote

[40 fathoms] 03/5/2023 07:15

Also this as well.

"The Board expects the Company to grow rapidly and deliver substantial, sustainable shareholder value in both the short and medium term."

"The outlook is very exciting as we have a full commercial team and a much broader portfolio and can win many more sizeable contracts as we build on our current position over the coming years."

[40 fathoms] 03/5/2023 07:14

This is exactly what I wanted to see

" The Company is targeting revenue growth in excess of the market growth rates with increasing levels of growth in the medium-term driving towards material profitability in 2025."

Very happy, although I would have put it at the top of the release rather than in the CFOs review.

[earwacks] 26/4/2023 12:20

Also investor briefing and webinar may 3rd. Questions can be presubmitted or at the webinar

[40 fathoms] 16/4/2023 06:35

Results on 3rd May, seems to have been a @2 week delay from what it appears they had originally intended.

[40 fathoms] 16/4/2023 06:33

@earwacks, the trials in question will be disease specific, as they have stated that they are pivotal trials. That means they are intended to demonstrate and confirm the safety and efficacy of a specific treatment in a specific indication.

They have told us that revenue from the contracts is to be recognised over 5 years, this is very long for a clinical trial standards and this would seem to indicate a slow, progressive or neurodevelopment disease. I think Huntingdon's or another rare from of dementia such as DLB is a pretty good guess, ALS might be another one that would fit the bill.

[earwacks] 15/4/2023 08:55

1c. It could be one. I don’t think the trials are disease specific, more that it is cognitive assessment of the brain for rare diseases, i.e. any disease that affects less than 1 in 2000.

[1c3479z] 13/4/2023 20:29

? Huntington's the disease in question?